FREEHOLD, NJ--(Marketwired - Sep 13, 2016) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst") would like to update shareholders regarding recent company developments. As previously announced, Medifirst Solutions, Inc., received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.
Medifirst is pleased to announce that it has made substantial progress in setting up its infrastructure for sales and compliance. The Company has engaged MDI Consultants, a leading provider of quality assurance, regulatory compliance, FDA consulting and clinical services to the healthcare industry. MDI Consultants will be hands-on with assisting and overseeing the implementation of the Company's internal controls and procedures as mandated by the FDA. These controls and procedures will be implemented in the Company's sales office, as well as at its manufacturer's facility. Commented President Bruce J. Schoengood, "We are very pleased to continue our relationship with MDI Consultants, who played a crucial role in successfully getting the FDA clearance, as Medifirst enters into the sales phase of operations."
In preparing to ramp up and roll out its sales division, Medifirst is pleased to announce that it has leased new office space in which to run its sales and training functions and operations which will include all FDA mandated internal controls and procedures. Medifirst's new office space, located in Marlboro, New Jersey, will provide professional space for training and testing. It will also handle all administrative functions for the Laser Division.
The Company previously announced that it was aggressively putting together a sales & distribution team to offer its Time Machine Lasers in the US market. Continued CEO Schoengood, "We have come to terms with an experienced National Sales Director with established credentials in the medical device industry and upon the completion of contracts and agreements, the Company will release an official announcement which is anticipated in the upcoming days. Additionally, the company has come to terms with additional top industry advisors and announcements are forthcoming as agreements are completed."
Continued CEO Schoengood, "Medifirst has also made substantial progress for financing, inventory and manufacturing, as well as marketing and advertising. All components of building a national brand with national sales are being addressed. We will be releasing updates on these developments in the upcoming days and weeks. The Company appreciates the patience of its shareholders and supporters during this exciting time."
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA") to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.